Mark Parrington

USPTO Granted Patents = 14 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 90(Granted Patents)

Company Filing History:

Connaught Laboratories Limited

patents

1 out of 1

Aventis Pateur Limited

patent

4. 1 out of 75

Aventis Pasteur Limited

patents

5. 1 out of 24

Sanofi Pasteur Biologics, LLC

patents

Years Active: 2000-2015

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9217158 - Replication-defective flavivirus vaccines and vaccine vectors (2015-12-22),

2. 8946174 - Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer (2015-02-03),

3. 8911991 - Multi-antigen vectors of melanoma (2014-12-16),

4. 8562970 - Modified CEA/B7 vector (2013-10-22),

5. 8530442 - Modified CEA nucleic acid and expression vectors (2013-09-10),

6. 8236776 - Modified CEA nucleic acid and expression vectors (2012-08-07),

7. 8207314 - Tumor antigens for prevention and/or treatment of cancer (2012-06-26),

8. 8021664 - Tumor antigens Bfa5 for prevention and/or treatment of cancer (2011-09-20),

9. 7851213 - Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer (2010-12-14),

10. 7786278 - Modified CEA nucleic acid and expression vectors (2010-08-31),

11. 7220826 - Expressing gp140 fragment of primary HIV-1 isolate (2007-05-22),

12. 6475780 - Alphavirus vectors for paramyxovirus vaccines (2002-11-05),

13. 6428324 - RNA respiratory syncytial virus vaccines (2002-08-06),

14. 6060308 - RNA respiratory syncytial virus vaccines (2000-05-09),

Title: Inventor Mark Parrington: Pioneering Innovations in Vaccine Development

Introduction

Mark Parrington is a notable inventor based in Bradford, CA, recognized for his significant contributions to the field of vaccine development. With an impressive portfolio of 14 patents, Parrington has been at the forefront of innovative solutions aimed at combating infectious diseases and cancer.

Latest Patents

Among his latest inventions, Mark Parrington has developed replication-defective flavivirus vaccines and vaccine vectors. This groundbreaking invention presents methods and compositions that enhance vaccine efficacy. Furthermore, he has also contributed to the field of oncology with his work on tumor antigens BFA4 and BCY1, which provides nucleic acids encoding polypeptides useful in the prevention and treatment of cancer. His improved vectors enable the insertion and expression of foreign genes, paving the way for advanced immunotherapeutic treatments.

Career Highlights

Throughout his career, Mark Parrington has made significant strides while working with esteemed organizations such as Sanofi Pasteur Inc. and Connaught Laboratories Limited. These experiences have provided him with invaluable insights into vaccine research and development, allowing him to create impactful inventions that address public health challenges.

Collaborations

Mark has collaborated with talented professionals in the field, including Linong Zhang and Benjamin Rovinski. Their teamwork has fostered the development of innovative solutions and contributed to the success of various projects pivotal in advancing vaccine technology.

Conclusion

Mark Parrington's work exemplifies the spirit of innovation in the healthcare field. His dedication to creating effective vaccines and therapeutic solutions has led to advancements that benefit countless individuals. As advancements in medicine continue, Parrington's contributions will remain a testament to the importance of innovation in tackling global health issues.

This text is generated by artificial intelligence and may not be accurate.